Cargando…
Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer
Breast cancer is clinically and biologically heterogeneous and is classified into different subtypes according to the molecular landscape of the tumor. Triple-negative breast cancer is a subtype associated with higher tumor aggressiveness, poor prognosis, and poor response to treatment. In metastati...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914403/ https://www.ncbi.nlm.nih.gov/pubmed/36766575 http://dx.doi.org/10.3390/diagnostics13030470 |
_version_ | 1784885661190324224 |
---|---|
author | El Hejjioui, Brahim Bouguenouch, Laila Melhouf, Moulay Abdelilah El Mouhi, Hind Bennis, Sanae |
author_facet | El Hejjioui, Brahim Bouguenouch, Laila Melhouf, Moulay Abdelilah El Mouhi, Hind Bennis, Sanae |
author_sort | El Hejjioui, Brahim |
collection | PubMed |
description | Breast cancer is clinically and biologically heterogeneous and is classified into different subtypes according to the molecular landscape of the tumor. Triple-negative breast cancer is a subtype associated with higher tumor aggressiveness, poor prognosis, and poor response to treatment. In metastatic breast cancer, approximately 6% to 10% of new breast cancer cases are initially staged IV (de novo metastatic disease). The number of metastatic recurrences is estimated to be 20–30% of all existing breast tumor cases, whereby the need to develop specific genetic markers to improve the prognosis of patients suffering from these deadly forms of breast cancer. As an alternative, liquid biopsy methods can minutely identify the molecular architecture of breast cancer, including aggressive forms, which provides new perspectives for more precise diagnosis and more effective therapeutics. This review aimed to summarize the current clinical evidence for the application of circulating tumor DNA in managing breast cancer by detailing the increased usefulness of this biomarker as a diagnostic, prognostic, monitoring, and surveillance marker for breast cancer. |
format | Online Article Text |
id | pubmed-9914403 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99144032023-02-11 Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer El Hejjioui, Brahim Bouguenouch, Laila Melhouf, Moulay Abdelilah El Mouhi, Hind Bennis, Sanae Diagnostics (Basel) Review Breast cancer is clinically and biologically heterogeneous and is classified into different subtypes according to the molecular landscape of the tumor. Triple-negative breast cancer is a subtype associated with higher tumor aggressiveness, poor prognosis, and poor response to treatment. In metastatic breast cancer, approximately 6% to 10% of new breast cancer cases are initially staged IV (de novo metastatic disease). The number of metastatic recurrences is estimated to be 20–30% of all existing breast tumor cases, whereby the need to develop specific genetic markers to improve the prognosis of patients suffering from these deadly forms of breast cancer. As an alternative, liquid biopsy methods can minutely identify the molecular architecture of breast cancer, including aggressive forms, which provides new perspectives for more precise diagnosis and more effective therapeutics. This review aimed to summarize the current clinical evidence for the application of circulating tumor DNA in managing breast cancer by detailing the increased usefulness of this biomarker as a diagnostic, prognostic, monitoring, and surveillance marker for breast cancer. MDPI 2023-01-27 /pmc/articles/PMC9914403/ /pubmed/36766575 http://dx.doi.org/10.3390/diagnostics13030470 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review El Hejjioui, Brahim Bouguenouch, Laila Melhouf, Moulay Abdelilah El Mouhi, Hind Bennis, Sanae Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer |
title | Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer |
title_full | Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer |
title_fullStr | Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer |
title_full_unstemmed | Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer |
title_short | Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer |
title_sort | clinical evidence of circulating tumor dna application in aggressive breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914403/ https://www.ncbi.nlm.nih.gov/pubmed/36766575 http://dx.doi.org/10.3390/diagnostics13030470 |
work_keys_str_mv | AT elhejjiouibrahim clinicalevidenceofcirculatingtumordnaapplicationinaggressivebreastcancer AT bouguenouchlaila clinicalevidenceofcirculatingtumordnaapplicationinaggressivebreastcancer AT melhoufmoulayabdelilah clinicalevidenceofcirculatingtumordnaapplicationinaggressivebreastcancer AT elmouhihind clinicalevidenceofcirculatingtumordnaapplicationinaggressivebreastcancer AT bennissanae clinicalevidenceofcirculatingtumordnaapplicationinaggressivebreastcancer |